Characteristics | Placebo (n = 21) | Rosuvastatin (n = 20) | p value | ||
---|---|---|---|---|---|
Baseline | Followup | Baseline | Followup | ||
Age, y | 58 ± 11 | 53 ± 16 | 0.22 | ||
Hemodynamics | |||||
HR (bpm) | 74 ± 11 | 72 ± 12 | 71 ± 10 | 70 ± 7 | 0.38 |
SBP (mm Hg) | 129 ± 16 | 127 ± 14 | 133 ± 15 | 130 ± 14 | 0.54 |
DBP (mm Hg) | 80 ± 9 | 77 ± 10 | 78 ± 10 | 76 ± 7 | 0.62 |
Aortic Valve Parameters | |||||
AVA (cm2) | 1.2 ± 0.4 | 1.1 ± 0.6 | 1.3 ± 0.5 | 1.1 ± 0.5 | 0.67 |
AV peak velocity (m/s) | 3.7 ± 0.2 | 4.4 ± 0.5* | 3.7 ± 0.1 | 4.4 ± 0.5† | 0.88 |
AV peak gradient (mm Hg) | 56 ± 4 | 80 ± 19* | 56 ± 4 | 79 ± 16† | 0.85 |
AV mean gradient (mm Hg) | 32 ± 5 | 47 ± 14* | 32 ± 4 | 46 ± 12† | 0.76 |
Left Heart Dimensions | |||||
IVS (mm) | 12 ± 2 | 12 ± 2 | 12 ± 2 | 12 ± 3 | 0.89 |
PWT (mm) | 11 ± 2 | 12 ± 2 | 11 ± 1 | 11 ± 2 | 0.58 |
LA (mm) | 36 ± 6 | 37 ± 7 | 37 ± 6 | 39 ± 7 | 0.58 |
LVEDD (mm) | 48 ± 4 | 47 ± 5 | 50 ± 5 | 49 ± 6 | 0.86 |
LVESD (mm) | 28 ± 5 | 27 ± 5 | 30 ± 5 | 30 ± 6 | 0.56 |
LV mass/BSA (g/m2) | |||||
Men | 94 ± 19 | 93 ± 17 | 94 ± 20 | 95 ± 11 | 0.54 |
Women | 81 ± 12 | 82 ± 15 | 82 ± 11 | 81 ± 17 | 0.68 |
EF (%) | 67 ± 7 | 67 ± 7 | 68 ± 8 | 69 ± 8 | 0.54 |
Conventional Diastolic Parameters | |||||
Mitral E velocity (cm/sec) | 83 ± 17 | 83 ± 26 | 84 ± 26 | 83 ± 27 | 0.44 |
Mitral A velocity (cm/sec) | 80 ± 27 | 80 ± 29 | 80 ± 27 | 79 ± 41 | 0.77 |
E/A ratio | 1.0 ± 0.2 | 1.0 ± 0.2 | 1.0 ± 0.2 | 1.0 ± 0.3 | 0.75 |
Tissue Doppler Imaging | |||||
Lateral S' | 8.1 ± 2.7 | 8.1 ± 1.7 | 8.3 ± 1.7 | 8.2 ± 1.6 | 0.62 |
Lateral E' | 6.0 ± 1.2 | 6.1 ± 2.1 | 6.1 ± 2.4 | 6.1 ± 1.3 | 0.74 |
Lateral A' | 10.1 ± 3.1 | 9.4 ± 3.5 | 10.6 ± 3.6 | 10.3 ± 2.3 | 0.55 |
E/E' (lateral) | 14 ± 3 | 15 ± 2 | 14 ± 5 | 15 ± 4 | 0.77 |